Sponsors (62)
The bill strengthens and speeds criminal enforcement against fentanyl-related substances—potentially reducing illicit supply and aiding prosecutors—at the cost of broader criminal exposure, faster-rulemaking with fewer procedural protections, increased public enforcement costs, and meaningful new limits and uncertainty for researchers and patients.
Law enforcement and prosecutors: clearer statutory definitions, an AG-published list, and congressional signals (including endorsement of McCray) make it easier and faster to identify, charge, and sustain prosecutions for fentanyl-related substances.
Government agencies and contractors: allowing interim final rules and immediate applicability lets enforcement and regulatory changes take effect faster, speeding compliance and operational response to emerging fentanyl threats.
People at risk of opioid overdose and communities: classifying more fentanyl analogues (and clarifying scope) can reduce illicit supply and support prevention and public-health enforcement efforts against dangerous fentanyl-related substances.
Researchers, clinicians, and patients: a broad structural Schedule I definition and expanded listings could restrict legitimate research and medical study of fentanyl-related compounds, slowing development of new therapies and clinical trials.
Individuals, labs, and defendants: the very broad definition and clarifying language preserving analogue status risk prosecutorial overreach, criminalizing substances with marginal relation to fentanyl and preserving prosecutions where prior uncertainty existed, raising due-process and liberty concerns.
Taxpayers and local governments: expanding Schedule I coverage and faster enforcement increases demand on criminal-justice systems, forensic testing, agency verifications, and prosecutions, raising public costs and administrative burdens.
Based on analysis of 7 sections of legislative text.
Treats any substance structurally related to fentanyl as Schedule I, adds a researcher notification pathway, and requires rapid AG rulemaking.
Classifies any substance that is structurally related to fentanyl as a Schedule I controlled substance, broadly expanding federal control over fentanyl analogs. It also creates an expedited notification-and-registration pathway for researchers at or funded by HHS, DOD, or VA (or working on drugs with an investigational use exemption), requires the Attorney General to issue implementing rules within six months (allowing immediate interim effect), and updates cross-references and definitions across several controlled-substance statutes. The change immediately makes fentanyl-related substances illegal at the federal Schedule I level when they meet the structural definition, authorizes the Attorney General to publish—but not limit—lists of such substances, and establishes procedural steps for practitioners to begin approved research after notifying the Attorney General and, if requested, obtaining verification from federal health agencies.
Introduced January 3, 2025 by H. Morgan Griffith · Last progress February 10, 2025